Skip to main content
Top
Published in: BMC Gastroenterology 1/2020

Open Access 01-12-2020 | Hepatocellular Carcinoma | Research article

High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study

Authors: Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Yee-Kit Tse, Becky Wing-Yan Yuen, Hester Wing-Sum Luk, Marco Ho-Bun Lam, Michael Kin-Kong Li, Ching Kong Loo, Owen Tak-Yin Tsang, Steven Woon-Choy Tsang, Henry Lik-Yuen Chan, Yun-Kwok Wing, Vincent Wai-Sun Wong

Published in: BMC Gastroenterology | Issue 1/2020

Login to get access

Abstract

Background

Because of high-risk behaviours, sedentary lifestyle and side effects of medications, psychiatric patients are at risk of viral hepatitis, alcohol-related liver disease and non-alcoholic fatty liver disease. We aimed to study the incidence of hepatocellular carcinoma (HCC) and cirrhotic complications in psychiatric patients.

Methods

We identified consecutive adult patients in all public hospitals and clinics in Hong Kong with psychiatric diagnoses between year 2003 and 2007 using the Clinical Data Analysis and Reporting System, which represents in-patient and out-patient data of approximately 80% of the 7.4-million local population. The patients were followed for liver-related events (HCC and cirrhotic complications) and deaths until December 2017. Age- and sex-standardized incidence ratio (SIR) of HCC in psychiatric patients to the general population was estimated by Poisson model.

Results

We included 105,763 psychiatric patients without prior liver-related events in the final analysis. During a median (interquartile range) follow-up of 12.4 (11.0–13.7) years, 1461 (1.4%) patients developed liver-related events; 472 (0.4%) patients developed HCC. Compared with the general population, psychiatric patients had increased incidence of HCC (SIR 1.42, 95% confidence interval [CI] 1.28–1.57, P < 0.001). The SIR was highest in patients with drug-induced (SIR 3.18, 95% CI 2.41–4.11, P < 0.001) and alcohol-induced mental disorders (SIR 2.98, 95% CI 2.30–3.81, P < 0.001), but was also increased in patients with psychotic disorders (SIR 1.39, 95% CI 1.16–1.65, P < 0.001) and mood disorders (SIR 1.16, 95% CI 1.00–1.34, P = 0.047). Liver disease was the fifth most common cause of death in this population, accounting for 595 of 10,614 (5.6%) deaths. Importantly, 569 (38.9%) patients were not known to have liver diseases at the time of liver-related events. The median age at HCC diagnosis (61 [range 26–83] years) was older and the median overall survival (8.0 [95% CI 5.0–10.9] months) after HCC diagnosis was shorter in this cohort of psychiatric patients than other reports from Hong Kong.

Conclusions

HCC, cirrhotic complications, and liver-related deaths are common in psychiatric patients, but liver diseases are often undiagnosed. More efforts are needed to identify liver diseases in the psychiatric population so that treatments and screening for HCC and varices can be provided to patients in need.
Appendix
Available only for authorised users
Literature
1.
go back to reference GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1151–210.CrossRef GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1151–210.CrossRef
2.
go back to reference Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiat. 2016;3(2):171–8.CrossRef Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiat. 2016;3(2):171–8.CrossRef
3.
go back to reference Wong VW, Wong GL, Chim AM, Cheng TF, Cheung SW, Lai CM, Szeto KJ, Tsang S, Wu SH, Yan KK, et al. Targeted hepatitis C screening among ex-injection drug users in the community. J Gastroenterol Hepatol. 2014;29(1):116–20.PubMedCrossRef Wong VW, Wong GL, Chim AM, Cheng TF, Cheung SW, Lai CM, Szeto KJ, Tsang S, Wu SH, Yan KK, et al. Targeted hepatitis C screening among ex-injection drug users in the community. J Gastroenterol Hepatol. 2014;29(1):116–20.PubMedCrossRef
4.
go back to reference Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic Steatohepatitis. Hepatology. 2019;69(6):2672–82.PubMedCrossRef Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic Steatohepatitis. Hepatology. 2019;69(6):2672–82.PubMedCrossRef
5.
go back to reference Vilar-Gomez E, Calzadilla-Bertot L, Wong VW, Castellanos M, Aller-de la Fuente R, Metwally M, Eslam M, Gonzalez-Fabian L, Alvarez-Quinones Sanz M, Conde-Martin AF, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155(2):443–57 e417.PubMedCrossRef Vilar-Gomez E, Calzadilla-Bertot L, Wong VW, Castellanos M, Aller-de la Fuente R, Metwally M, Eslam M, Gonzalez-Fabian L, Alvarez-Quinones Sanz M, Conde-Martin AF, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155(2):443–57 e417.PubMedCrossRef
6.
go back to reference Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, et al. Nonalcoholic Steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–55 e743.PubMedCrossRef Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, et al. Nonalcoholic Steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–55 e743.PubMedCrossRef
7.
go back to reference Marazziti D, Rutigliano G, Baroni S, Landi P, Dell'Osso L. Metabolic syndrome and major depression. CNS spectrums. 2014;19(4):293–304.PubMedCrossRef Marazziti D, Rutigliano G, Baroni S, Landi P, Dell'Osso L. Metabolic syndrome and major depression. CNS spectrums. 2014;19(4):293–304.PubMedCrossRef
8.
go back to reference Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K, Jara B. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74–85.PubMedCrossRef Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K, Jara B. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74–85.PubMedCrossRef
9.
go back to reference Dashti HS, Follis JL, Smith CE, Tanaka T, Cade BE, Gottlieb DJ, Hruby A, Jacques PF, Lamon-Fava S, Richardson K, et al. Habitual sleep duration is associated with BMI and macronutrient intake and may be modified by CLOCK genetic variants. Am J Clin Nutr. 2015;101(1):135–43.PubMedCrossRef Dashti HS, Follis JL, Smith CE, Tanaka T, Cade BE, Gottlieb DJ, Hruby A, Jacques PF, Lamon-Fava S, Richardson K, et al. Habitual sleep duration is associated with BMI and macronutrient intake and may be modified by CLOCK genetic variants. Am J Clin Nutr. 2015;101(1):135–43.PubMedCrossRef
10.
go back to reference Chan JW, Lam SP, Li SX, Yu MW, Chan NY, Zhang J, Wing YK. Eveningness and insomnia: independent risk factors of nonremission in major depressive disorder. Sleep. 2014;37(5):911–7.PubMedPubMedCentralCrossRef Chan JW, Lam SP, Li SX, Yu MW, Chan NY, Zhang J, Wing YK. Eveningness and insomnia: independent risk factors of nonremission in major depressive disorder. Sleep. 2014;37(5):911–7.PubMedPubMedCentralCrossRef
11.
go back to reference Fuller BE, Rodriguez VL, Linke A, Sikirica M, Dirani R, Hauser P. Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. Gen Hosp Psychiatry. 2011;33(3):232–7.PubMedCrossRef Fuller BE, Rodriguez VL, Linke A, Sikirica M, Dirani R, Hauser P. Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. Gen Hosp Psychiatry. 2011;33(3):232–7.PubMedCrossRef
12.
go back to reference Youssef NA, Abdelmalek MF, Binks M, Guy CD, Omenetti A, Smith AD, Diehl AM, Suzuki A. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int. 2013;33(7):1062–70.PubMedCrossRef Youssef NA, Abdelmalek MF, Binks M, Guy CD, Omenetti A, Smith AD, Diehl AM, Suzuki A. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int. 2013;33(7):1062–70.PubMedCrossRef
13.
go back to reference Castillo-Sanchez M, Fabregas-Escurriola M, Berge-Baquero D, Fernandez-San Martin M, Boreu QF, Goday-Arno A. Risk of underdiagnosis of hypertension in schizophrenia patients. Clin Exp Hypertens. 2018;40(2):167–74.PubMedCrossRef Castillo-Sanchez M, Fabregas-Escurriola M, Berge-Baquero D, Fernandez-San Martin M, Boreu QF, Goday-Arno A. Risk of underdiagnosis of hypertension in schizophrenia patients. Clin Exp Hypertens. 2018;40(2):167–74.PubMedCrossRef
14.
go back to reference van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama. 2012;308(24):2584–93.PubMedCrossRef van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama. 2012;308(24):2584–93.PubMedCrossRef
15.
go back to reference Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58(5):1537–47.PubMedCrossRef Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58(5):1537–47.PubMedCrossRef
18.
go back to reference Man LP, Ho AW, Wong SH. Excess mortality for operated geriatric hip fracture in Hong Kong. Hong Kong Med J. 2016;22(1):6–10.PubMed Man LP, Ho AW, Wong SH. Excess mortality for operated geriatric hip fracture in Hong Kong. Hong Kong Med J. 2016;22(1):6–10.PubMed
19.
go back to reference Wong JC, Chan HL, Tse YK, Yip TC, Wong VW, Wong GL. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. Aliment Pharmacol Ther. 2017;46(10):1001–10.PubMedCrossRef Wong JC, Chan HL, Tse YK, Yip TC, Wong VW, Wong GL. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. Aliment Pharmacol Ther. 2017;46(10):1001–10.PubMedCrossRef
20.
go back to reference Wong GL, Chan HL, Tse YK, Yip TC, Lam KL, Lui GC, Szeto CC, Wong VW. Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. Aliment Pharmacol Ther. 2018;48(9):984–92.PubMedCrossRef Wong GL, Chan HL, Tse YK, Yip TC, Lam KL, Lui GC, Szeto CC, Wong VW. Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. Aliment Pharmacol Ther. 2018;48(9):984–92.PubMedCrossRef
21.
go back to reference Yip TC, Chan HL, Tse YK, Lam KL, Lui GC, Wong VW, Wong GL. On-treatment improvement of MELD score reduces death and hepatic events in patients with hepatitis B-related cirrhosis. Am J Gastroenterol. 2018;113(11):1629–38.PubMedCrossRef Yip TC, Chan HL, Tse YK, Lam KL, Lui GC, Wong VW, Wong GL. On-treatment improvement of MELD score reduces death and hepatic events in patients with hepatitis B-related cirrhosis. Am J Gastroenterol. 2018;113(11):1629–38.PubMedCrossRef
22.
go back to reference Lai JC, Wong GL, Yip TC, Tse YK, Lam KL, Lui GC, Chan HL, Wong VW. Chronic hepatitis B increases liver-related mortality of patients with acute hepatitis E: a Territorywide cohort study from 2000 to 2016. Clin Infect Dis. 2018;67(8):1278–84.PubMedCrossRef Lai JC, Wong GL, Yip TC, Tse YK, Lam KL, Lui GC, Chan HL, Wong VW. Chronic hepatitis B increases liver-related mortality of patients with acute hepatitis E: a Territorywide cohort study from 2000 to 2016. Clin Infect Dis. 2018;67(8):1278–84.PubMedCrossRef
23.
go back to reference Yip TC, Wong GL, Wong VW, Tse YK, Lui GC, Lam KL, Chan HL. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol. 2017;68(1):63–72.CrossRef Yip TC, Wong GL, Wong VW, Tse YK, Lui GC, Lam KL, Chan HL. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol. 2017;68(1):63–72.CrossRef
26.
go back to reference Wong GL, Chan HL, Loo CK, Hui YT, Fung JY, Cheung D, Chung C, Chim AM, Wong VW. Hong Kong Association for the Study of liver D: change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. J Gastroenterol Hepatol. 2019;34(9):1641–7. Wong GL, Chan HL, Loo CK, Hui YT, Fung JY, Cheung D, Chung C, Chim AM, Wong VW. Hong Kong Association for the Study of liver D: change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. J Gastroenterol Hepatol. 2019;34(9):1641–7.
27.
go back to reference Hui YT, Wong GLH, Fung JYY, Chan HLY, Leung NWY, Liu SD, Liu K, Ma YK, But DYK, Mak WY, et al. Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. Liver Int. 2018;38(11):1911–9.PubMedCrossRef Hui YT, Wong GLH, Fung JYY, Chan HLY, Leung NWY, Liu SD, Liu K, Ma YK, But DYK, Mak WY, et al. Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. Liver Int. 2018;38(11):1911–9.PubMedCrossRef
28.
go back to reference Liu KSH, Seto WK, Lau EHY, Wong DK, Lam YF, Cheung KS, Mak LY, Ko KL, To WP, Law MWK, et al. A Territorywide prevalence study on blood-borne and enteric viral hepatitis in Hong Kong. J Infect Dis. 2019;219(12):1924–33.PubMedCrossRef Liu KSH, Seto WK, Lau EHY, Wong DK, Lam YF, Cheung KS, Mak LY, Ko KL, To WP, Law MWK, et al. A Territorywide prevalence study on blood-borne and enteric viral hepatitis in Hong Kong. J Infect Dis. 2019;219(12):1924–33.PubMedCrossRef
29.
go back to reference Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Woo J, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61(3):409–15.PubMedCrossRef Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Woo J, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61(3):409–15.PubMedCrossRef
30.
go back to reference Wong VW, Wong GL, Yeung DK, Lau TK, Chan CK, Chim AM, Abrigo JM, Chan RS, Woo J, Tse YK, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2015;62(1):182–9.PubMedCrossRef Wong VW, Wong GL, Yeung DK, Lau TK, Chan CK, Chim AM, Abrigo JM, Chan RS, Woo J, Tse YK, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2015;62(1):182–9.PubMedCrossRef
31.
go back to reference Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol. 2017;2(4):288–97.PubMedCrossRef Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol. 2017;2(4):288–97.PubMedCrossRef
33.
go back to reference Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–21.PubMedCrossRef Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–21.PubMedCrossRef
34.
go back to reference Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691–700 e1693.PubMedCrossRef Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691–700 e1693.PubMedCrossRef
35.
go back to reference Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, Shu SS, Chan AW, Yeung MW, Chan JC, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65(8):1359–68.PubMedCrossRef Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, Shu SS, Chan AW, Yeung MW, Chan JC, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65(8):1359–68.PubMedCrossRef
36.
37.
go back to reference Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, Suri D, Thorburn D, Sennett K, Morgan S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71(2):371–8. Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, Suri D, Thorburn D, Sennett K, Morgan S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71(2):371–8.
38.
go back to reference Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28(10):1660–5.PubMedCrossRef Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28(10):1660–5.PubMedCrossRef
39.
go back to reference Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, So WY, Cheng AY, Tong PC, Chan FK, et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24(8):1215–22.PubMedCrossRef Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, So WY, Cheng AY, Tong PC, Chan FK, et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24(8):1215–22.PubMedCrossRef
40.
go back to reference Muller MJ, Willmann O, Rieger A, Fenk A, Selberg O, Lautz HU, Burger M, Balks HJ, von zur Muhlen A, Schmidt FW. Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology. 1992;102(6):2033–41.PubMedCrossRef Muller MJ, Willmann O, Rieger A, Fenk A, Selberg O, Lautz HU, Burger M, Balks HJ, von zur Muhlen A, Schmidt FW. Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology. 1992;102(6):2033–41.PubMedCrossRef
41.
go back to reference Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010;59(9):1279–87.PubMedCrossRef Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010;59(9):1279–87.PubMedCrossRef
42.
go back to reference Hashimoto S, Yatsuhashi H, Abiru S, Yamasaki K, Komori A, Nagaoka S, Saeki A, Uchida S, Bekki S, Kugiyama Y, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment. PLoS One. 2016;11(9):e0163644.PubMedPubMedCentralCrossRef Hashimoto S, Yatsuhashi H, Abiru S, Yamasaki K, Komori A, Nagaoka S, Saeki A, Uchida S, Bekki S, Kugiyama Y, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment. PLoS One. 2016;11(9):e0163644.PubMedPubMedCentralCrossRef
43.
go back to reference Park SH, Ishino R. Liver injury associated with antidepressants. Curr Drug Saf. 2013;8(3):207–23.PubMedCrossRef Park SH, Ishino R. Liver injury associated with antidepressants. Curr Drug Saf. 2013;8(3):207–23.PubMedCrossRef
44.
go back to reference Chen VC, Lin CF, Hsieh YH, Liang HY, Huang KY, Chiu WC, Lee Y, McIntyre RS, Chan HL. Hepatocellular carcinoma and antidepressants: a nationwide population-based study. Oncotarget. 2017;8(18):30464–70.PubMed Chen VC, Lin CF, Hsieh YH, Liang HY, Huang KY, Chiu WC, Lee Y, McIntyre RS, Chan HL. Hepatocellular carcinoma and antidepressants: a nationwide population-based study. Oncotarget. 2017;8(18):30464–70.PubMed
45.
go back to reference Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on alcohol and related conditions III. JAMA psychiatry. 2015;72(8):757–66.PubMedPubMedCentralCrossRef Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on alcohol and related conditions III. JAMA psychiatry. 2015;72(8):757–66.PubMedPubMedCentralCrossRef
46.
go back to reference Ajmera V, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE, Neuschwander-Tetri BA, Terrault N. Nonalcoholic Steatohepatitis clinical research N: among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic Steatosis and Steatohepatitis. Clinl Gastroenterol Hepatol. 2018;16(9):1511–20 e1515.CrossRef Ajmera V, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE, Neuschwander-Tetri BA, Terrault N. Nonalcoholic Steatohepatitis clinical research N: among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic Steatosis and Steatohepatitis. Clinl Gastroenterol Hepatol. 2018;16(9):1511–20 e1515.CrossRef
47.
go back to reference Killaspy H, Banerjee S, King M, Lloyd M. Prospective controlled study of psychiatric out-patient non-attendance. Characteristics and outcome. Br J psychiatry. 2000;176:160–5.PubMedCrossRef Killaspy H, Banerjee S, King M, Lloyd M. Prospective controlled study of psychiatric out-patient non-attendance. Characteristics and outcome. Br J psychiatry. 2000;176:160–5.PubMedCrossRef
Metadata
Title
High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study
Authors
Terry Cheuk-Fung Yip
Grace Lai-Hung Wong
Yee-Kit Tse
Becky Wing-Yan Yuen
Hester Wing-Sum Luk
Marco Ho-Bun Lam
Michael Kin-Kong Li
Ching Kong Loo
Owen Tak-Yin Tsang
Steven Woon-Choy Tsang
Henry Lik-Yuen Chan
Yun-Kwok Wing
Vincent Wai-Sun Wong
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2020
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-020-01277-0

Other articles of this Issue 1/2020

BMC Gastroenterology 1/2020 Go to the issue